A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes.
A randomised phase 2 dose-finding study of the novel once weekly human GLP-1 - Analog, Semaglutide compared with placebo and open label liglutide in patients with type 2 diabetes